Assisted hatching focuses on helping the embryo break out of its protective shell, the zona pellucida, so it can hatch and implant. In IVF, the embryo must hatch from this zona to attach to the uterine lining. This is achieved by thinning the zona or creating a tiny opening using methods like laser, chemical treatment, or gentle mechanical technique. The goal is to reduce the barrier to hatching and improve the chance of implantation, especially in cases where the zona is thickened, or after freezing and thawing, or in patients with factors that raise implantation risk. The other options involve different ART steps: embryo biopsy for genetic testing, cryopreservation of embryos, and fertilization by ICSI, none of which describe the hatching process.

Reduced quantity and quality of oocytes in the ovaries is described by diminished ovarian reserve. This concept explains fertility impairment because as the ovarian reserve shrinks, the pool of viable eggs to ovulate declines, and the eggs that remain may be less competent, lowering the chances of successful conception. Clinically, reserve is often assessed with markers such as anti-Müllerian hormone levels, day-3 FSH, and antral follicle count, with age being a strong influencing factor. Polycystic ovarian syndrome involves irregular ovulation and hyperandrogenism rather than a reduced ovarian egg reserve, so it isn’t defined by diminished egg quantity/quality. Ovarian hyperstimulation syndrome is a complication that can occur with fertility drugs, not a baseline description of the ovary’s capacity. Premature ovarian failure (primary ovarian insufficiency) describes very early loss of ovarian function and may present with amenorrhea, but diminished ovarian reserve is the broader term that captures reduced egg quantity and quality that can underlie infertility, at any age.

When you don’t have ROI data, use external benchmarks and a structured value model to estimate monetary impact. Public benchmarks and industry averages give a realistic reference point by showing what similar initiatives typically achieve, which you can translate into dollars using relevant metrics like revenue lift, cost savings, or productivity gains. A structured value model lays out a clear, repeatable method to quantify benefits: you specify baseline performance, target improvements, and unit economics, then compute the expected monetary impact with explicit assumptions and ranges. For example, for a new training program, you’d look at industry ROI for similar trainings, estimate the expected uplift per participant, and multiply by the number of participants to estimate total value. Internal audits of past projects rely on prior ROI data, which you don’t have in this scenario, so they’re not as useful for new estimates. Marketing plans are plans, not actual outcomes, so they don’t provide reliable monetary estimates. Random guesses have no basis and aren’t defensible.

Understanding terminology for male sexual function helps distinguish what isn’t happening: ejaculation, orgasm, or sperm production. Anejaculation describes not ejecting semen during arousal and stimulation—the outward release simply doesn’t occur, even though arousal is present. This directly matches “lack of external ejaculation.” Anorgasmia is about not reaching orgasm, which is a broader peak in the sexual response and isn’t the same as failing to ejaculate. Azoospermia refers to having no sperm in the semen, which concerns sperm content rather than the act of ejaculation itself. Asperia isn’t a recognized medical term in this context. So the best fit for lack of external ejaculation is anejaculation.